Literature DB >> 16154842

Epstein-Barr virus genome level, T-cell clonality and the prognosis of angioimmunoblastic T-cell lymphoma.

Riko Kawano1, Koichi Ohshima, Shinichi Wakamatsu, Junji Suzumiya, Masahiro Kikuchi, Kazuo Tamura.   

Abstract

BACKGROUND AND OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AILT) is a peripheral T-cell tumor of unknown etiology with variable biological and clinical presentations. Previous clonality studies have shown heterogeneous clonal restrictions of B- and T-cell populations in this tumor. AILT is characterized by the presence of increased numbers of Epstein-Barr virus (EBV) infected cells. The aim of this study was to clarify the correlation between clonality, EBV and prognosis. DESIGN AND METHODS: Frozen material from 59 cases of AILT was used for DNA isolation and gene analysis by Southern blotting. A real-time polymerase chain reaction was used to quantify the amount of EBV-DNA in the tissue. Survival data were retrieved from clinical records.
RESULTS: Clonal T cells were found in 15/50 and clonal B-cells in 2/50 tumors, using Southern blot analysis. Bands of EBV-W were found in 10/50 tumors. Survival rate did not correlate with either T-cell clonality (p=0.84), or presence of EBV-infected cells (p=0.84). The EBV-DNA copy number in EBV-infected tissue did not correlate with disease progression (p=0.87). The survival rate and clinical status according to the international prognostic index (IPI) did not correlate with T-cell clonality status or EBV infection. INTERPRETATION AND
CONCLUSIONS: AILT remains a heterogeneous disease with clinical behavior that varies irrespective of the genomic parameters investigated.

Entities:  

Mesh:

Year:  2005        PMID: 16154842

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  6 in total

1.  Lymphoma-like T cell infiltration in liver is associated with increased copy number of dominant negative form of TGFβ receptor II.

Authors:  Weici Zhang; Masanobu Tsuda; Guo-Xiang Yang; Koichi Tsuneyama; Xiao-Song He; Aftab A Ansari; William M Ridgway; Ross L Coppel; Zhe-Xiong Lian; Patrick S C Leung; M Eric Gershwin
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

2.  Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.

Authors:  Yuna Lee; Keun-Wook Lee; Jee-Hyun Kim; Soo-Mee Bang; Jong Seok Lee; Byeong-Bae Park; Won Seok Kim; Cheolwon Suh; Jung Hun Kang; Baek Yeol Ryoo; Jae Hoon Lee; Dong Bok Shin
Journal:  Korean J Intern Med       Date:  2008-03       Impact factor: 2.884

3.  A difficult case of angioimmunoblastic T-cell lymphoma to diagnose.

Authors:  Elisabetta Sachsida-Colombo; Livia Caroline Barbosa Mariano; Fernanda Queiróz Bastos; Amanda Bruder Rassi; Luís Alberto de Pádua Covas Lage; Ariel Barreto; Sheila Siqueira; Juliana Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2015-12-14

4.  B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma.

Authors:  Yufeng Shang; Xiaorui Fu; Yu Chang; Yanan Li; Mingzhi Zhang
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

5.  EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma.

Authors:  Ahmed E Eladl; Kazuyuki Shimada; Yuka Suzuki; Taishi Takahara; Seiichi Kato; Kei Kohno; Ahmed Ali Elsayed; Chun-Chieh Wu; Takashi Tokunaga; Tomohiro Kinoshita; Mamiko Sakata-Yanagimoto; Shigeo Nakamura; Akira Satou
Journal:  Cancer Med       Date:  2019-12-02       Impact factor: 4.452

Review 6.  New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP.

Authors:  Rana Mhaidly; Adrien Krug; Philippe Gaulard; François Lemonnier; Jean-Ehrland Ricci; Els Verhoeyen
Journal:  Oncogenesis       Date:  2020-08-14       Impact factor: 7.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.